Leica Biosystems Unites Pharma, Pathologists, and Oncologists to Help Shape the Future of Digital Pathology and Enable More Precise Patient Therapies

[DEER PARK, Ill. — June 9, 2026] — Leica Biosystems, a Danaher company and a global leader in end to end anatomic and digital pathology solutions, is advancing how pharmaceutical organizations scale digital and computational pathology to support AI enabled biomarker discovery and companion diagnostics (CDx) development. The company recently convened senior leaders from leading pharmaceutical companies along with academic and clinical experts from top organizations for Leica Biosystems Open Day—an interactive forum focused on moving computational pathology from pilot programs to enterprise adoption.

Presenters highlighted advancements in digital and computational pathology workflows, including Matthew Hanna, MD, Vice Chair of Pathology Informatics, Associate Professor of Pathology at the University of Pittsburgh Department of Pathology, and Marilyn Bui, MD, PhD, Senior Member and Professor of Pathology and Machine Learning of Moffitt Cancer Center. Marilyn shared insights on how digital pathology and AI can enhance diagnostic precision, streamline workflows, and improve pathology reporting. She expressed enthusiasm about Leica Biosystems’ role in advancing large-scale clinical implementation of digital pathology at her home institution, complementing its longstanding contributions to research and education.

The event reflected Leica Biosystems’ growing collaboration with pharmaceutical companies working to advance digital and computational pathology at scale, particularly in support of biomarker discovery, companion diagnostics (CDx) development, and the broader promise of precision medicine.

Held on May 28, 2026, Leica Biosystems Open Day focused on how AI‑enabled image analysis, standardized digital workflows, and translational collaboration can help bridge the gap between biomarker discovery and clinical impact—one of the most pressing challenges facing drug development today.

“Digital and computational pathology are no longer emerging technologies; they are foundational capabilities for modern drug development,” said Gustavo Perez-Fernandez, Group Executive, Diagnostics, Danaher and President, Leica Biosystems. “Leica Biosystems Open Day was designed as an education-first forum—bringing our partners together around a shared objective: translating scientific innovation into clinical reality, faster and with greater confidence. As the market leader in digital and computational pathology, with the largest digital pathology install base, Leica Biosystems is well positioned to help teams move from discovery through CDx commercialization.”

From Vision to Practice: Scaling Precision Medicine
Throughout the day, speakers and panelists explored the practical implementation of computational pathology, including AI-assisted biomarker analysis, regulatory considerations, and real-world deployment across global organizations. Sessions addressed topics ranging from guidelines for AI-enabled biomarker adoption to pharma-pathology collaboration models designed to de-risk and accelerate clinical programs.

A dedicated panel discussion examined digital pathology’s ability to help scale precision therapies, aligning scientific rigor with operational feasibility across multi‑site clinical trials.

“Pharma teams are under increasing pressure to generate high quality biomarker data earlier and at greater scale,” said Karan Arora, Senior Vice President of Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. “What we heard consistently at Leica Biosystems Open Day is the need for integrated, enterprise ready platforms that combine imaging, AI, and workflow standardization, so insights can be translated into confident decisions that ultimately help get the right therapies to the right patients, faster. Leica Biosystems is the only company offering true end-to-end ownership of the pathology workflow, from research discovery through diagnosis and analysis, and that is exactly where we continue to invest and lead."

Momentum Builds on Recent Partnership Announcements
Leica Biosystems Open Day builds on recently announced strategic partnerships which include expanding CDx development and commercialization capabilities to enable more precise patient selection and improved therapeutic outcomes, ultimately enabling improved therapy selection for patients. Recently announced partnerships include Lunit and Indica Labs to develop AI-Powered Computational Pathology Algorithms for PD-L1; CellCarta to bring a proven CDx joint development from China to bioparhma sponsors globally; and DiaDeep to bring new AI-driven pathology applications to the Aperio AI Store.

Together, these collaborations reflect a broader industry shift toward deep, long‑term partnerships between technology providers and pharmaceutical companies—moving beyond point solutions to fully integrated, end‑to‑end approaches.

“Pharmaceutical innovation depends on ecosystems, not silos,” said Rob Monroe, Chief Medical Officer, Leica Biosystems. “By convening leaders across pharma, pathology, and technology, Leica Biosystems Open Day reinforced how we help partners compress timelines, reduce risk, and bring precision medicine to patients faster.”

While Leica Biosystems Open Day has concluded, the conversation and momentum continues—signaling an unwavering commitment from Leica Biosystems to listening, collaborating, and pioneering meaningful innovations that shape the future of diagnostics and precision medicine to improve lives worldwide.

About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in end-to-end anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of Advancing Cancer Diagnostics, Improving Lives is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at www.leicabiosystems.com.

About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.